ProQR Therapeutics NV (STU:0PQ) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0PQ ProQR Therapeutics NV STU:0PQ
51 GF Score
Price €1.51
GF Value €1.79
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:0PQ vs CRBP, NRXP, CRBU: Short Interest Comparison

For the Biotechnology subindustry, ProQR Therapeutics NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProQR Therapeutics NV Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Short Interest distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Short Interest falls into.


STU:0PQ
51GF Score
ProQR Therapeutics NV STU:0PQ
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ProQR Therapeutics NV (STU:0PQ) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of €1.51 is trading 15.9% below its estimated GF Value™ of €1.79. GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.

Key valuation signals for STU:0PQ:

  • Short Interest:
  • GF Value™: €1.79 vs. price of €1.51 (15.9% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:0PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
51GF Score

Get the complete analysis for STU:0PQ

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€1.79
GF Value